ArticleCureus2025
Neutrophil-to-Lymphocyte Ratio (NLR): A Predictor of Microvascular Complications in Type 2 Diabetes Mellitus.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Diabetes is a major public health challenge in India, and simple, low-cost tools are needed to detect early microvascular complications. We explored whether the neutrophil-to-lymphocyte ratio (NLR) can help predict such complications in people with type 2 diabetes. Methods We conducted a cross-sectional study in 2022-23, enrolling 150 patients aged 40-80 years with type 2 diabetes. Each participant underwent a detailed clinical evaluation, including blood sugar, HbA1c, NLR, and screening for diabetic neuropathy, nephropathy, and retinopathy. Results The mean age of participants was 58.9 ± 9.3 years. Comorbidities were present in 84% of participants (n=126), mainly dyslipidaemia (n=102, 68%) and hypertension (n=86, 57.3%). Almost half of the patients (n=73, 48.6%) had neuropathy, 42.6% (n=64) had nephropathy, and about one-quarter (n=39, 26%) had retinopathy. The mean NLR was higher in patients with microvascular complications than in those without (p < 0.001). The NLR correlated strongly with neuropathy (r = 0.72, p < 0.001) and moderately with nephropathy (r = 0.39, p < 0.001) and retinopathy (p < 0.001). A higher NLR was also associated with poor glycaemic control (HbA1c) (r = 0.41, p < 0.001) and central obesity (waist-to-hip ratio) (r = 0.31, p < 0.001). NLR showed high prediction for neuropathy (cut-off = 1.75, AUC = 0.926, sensitivity 93.2%, specificity 74%) and retinopathy (cut-off = 2.15, AUC = 0.942, sensitivity 94.9%, specificity 78.4%), but not for nephropathy. Conclusion Although the NLR correlated significantly with all microvascular complications in T2DM, it showed strong predictive ability only for neuropathy and retinopathy. Thus, it may serve as a cost-effective marker for predicting microvascular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.